Flmodafinil Stats & Data

Evidence status: there are no published human pharmacokinetic or controlled dosing studies for flmodafinil (NLS‑4) as of November 11, 2025; most practical guidance derives from preclinical work on NLS‑4 and community reports. In mice, NLS‑4 produced robust wake-promotion at lower doses than modafinil and did not show rebound hypersomnia, indicating higher potency but not necessarily a longer duration in humans. Modafinil (the parent scaffold) is an atypical dopamine transporter blocker and can induce/inhibit CYP enzymes with repeated dosing; flmodafinil’s DDI profile in humans is unknown, so it is prudent to assume similar interaction risks, particularly with CYP2C19/3A4 substrates and hormonal contraceptives, if using on sequential days. Very rare but serious dermatologic reactions (SJS/TEN) have been reported with armodafinil/modafinil; any widespread rash, mucosal lesions, fever, or systemic symptoms warrant immediate discontinuation and medical evaluation. Avoid intranasal use: users frequently report chemical irritation and unpleasant drip with little benefit over oral; oral early-morning dosing minimizes insomnia. Stimulant-stacking (other RX stimulants, heavy caffeine) raises cardiovascular/anxiety burden without clear cognitive advantage. Tolerance can build with repeated use; community logs describe marked attenuation after 1–2 weeks of daily/twice‑daily dosing—spacing use (several drug‑free days per week) helps preserve effect. Avoid heating/smoking/vaping powders: modafinil‑class compounds thermally degrade into benzhydryl byproducts under GC‑like temperatures, underscoring unknown pyrolysis products and potential toxicity if smoked. Use an accurate 0.001 g scale; vendor purity varies and mislabeling is possible in unregulated markets.